Isakoff, Steven J <br/><br/>
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.  [electronic resource] 

 -  Future oncology (London, England)  Feb 2017 
 - 307-320 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1744-8301 
<br/><br/><label>Standard No.: </label>10.2217/fon-2016-0412  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>BRCA1 Protein--genetics<br/>BRCA2 Protein--genetics<br/>Benzimidazoles--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Carboplatin--administration & dosage<br/>Clinical Protocols<br/>Dacarbazine--administration & dosage<br/>Drug Monitoring<br/>Female<br/>Humans<br/>Models, Statistical<br/>Paclitaxel--administration & dosage<br/>Research Design<br/>Sample Size<br/>Temozolomide